Attorney Docket No.: Q93245

AMENDMENTS TO THE DRAWINGS

Attached are three (3) replacement sheets of drawings (Figures 1-3).

Attachment: Replacement Sheets

RESPONSE TO EX PARTE QUAYLE OFFICE ACTION Attorney Docket No.: Q93245

Application No.: 10/568,754

REMARKS

In the Office Action of April 10, 2007, the Examiner objected to Figures 1 and 2, filed on February 21, 2006, as "not considered to be the best available." Upon review of master copies of Figures 1 and 2, Applicants submit that the drawings filed February 21, 2006, were indeed the best available. Nevertheless, Applicants submit herewith replacement drawings for this application in the event that the Examiner considers the replacement drawings to be better copies. In this regard, Applicants note that Fig. 2 shows a degraded surface (see, e.g., page 10, lines 6-9 in the specification), which is why Fig. 2 appears as it does.

In the Office Action of April 10, 2007, the Examiner further indicates that the instant application does not contain a "Sequence Listing," or a copy thereof in computer readable form. Applicants hereby submit a sequence listing and an identical copy thereof in computer readable form, as required by 37 C.F.R. § 1.821(c) and (e), with the Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825 submitted herewith. Applicants note that the sequence listing was actually present in the international application PCT/JP2004/012307, but was inadvertently omitted from this national stage application, and thus is being added back into the specification by the above amendment directing its entry into the specification.

Finally, to complete the record for this case, Applicants submit herewith a Supplementary European Search Report dated May 3, 2007. Since the search report only cites a reference (U.S. Patent 6,376,213) which has already been considered by the Examiner (see the PTO/SB/08 form filed May 22, 2006, an initialed copy of which was attached to the Office Action of October 5, 2006), an Information Disclosure Statement citing that reference is not being filed.

RESPONSE TO EX PARTE QUAYLE OFFICE ACTION

Application No.: 10/568,754

Attorney Docket No.: Q93245

In view of the above, reconsideration and allowance of this application are now believed

to be in order, and such actions are hereby solicited. If any points remain in issue which the

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is

kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 33,725

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 11, 2007

5

Application No.: 10/568,754 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damag and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
Aprinitial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE